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A B S T R A C T
Oxidative stress is a key player in both chronic and acute brain disease due to the higher metabolic demand of
the brain. Among the producers of free radicals, NADPH-oxidase (NOX) is a major contributor to oxidative stress
in neurological disorders. In the brain, the superoxide produced by NOX is mainly found in leukocytes. However,
recent studies have reported that it can be found in several other cell types. NOX has been reported to regulate
neuronal signaling, memory processing, and central cardiovascular homeostasis. However, overproduction of
NOX can contribute to neurotoxicity, CNS degeneration, and cardiovascular disorders. Regarding the above
functions, NOX has been shown to play a crucial role in chronic CNS diseases like Parkinson’s disease (PD),
Alzheimer’s disease (AD), Huntington’s disease (HD), multiple sclerosis (MS), and amyotrophic lateral sclerosis
(ALS), and in acute CNS disorders such as stroke, spinal cord injury, traumatic brain injury (TBI), and related
cerebrovascular diseases. NOX is a multi-subunit complex consisting of two membrane-associated and four
cytosolic subunits. Thus, in recent years, inhibition of NOX activity has drawn a great deal of attention from
researchers in the field of treating chronic and acute CNS disorders and preventing secondary complications.
Mounting evidence has shown that NOX inhibition is neuroprotective and that inhibiting NOX in circulating
immune cells can improve neurological disease conditions. This review summarizes recent studies on the
therapeutic effects and pharmacological strategies regarding NOX inhibitors in chronic and acute brain diseases
and focuses on the hurdles that should be overcome before their clinical implementation.
Introduction
Mammalian brain has a high oxidative metabolic rate with a low
level of antioxidant and neuroprotective enzyme activity. The presence
of copious readily oxidizable membrane polyunsaturated fatty acids
(PUFAs) and endogenous production of reactive oxygen species (ROS)
makes the central nervous system (CNS) vulnerable to oxidative stress
damage (Schonfeld and Reiser, 2013). These PFAs and ROS are med-
iators of several chronic and acute neurodegenerative diseases. Chronic
CNS disorders which are related to oxidative stress include dopami-
nergic motor neuron disease in the brain substantia nigra leading to
Parkinson’s disease (PD); dementia-related disorders that include issues
such as language problem, disorientation, depression, lack of motiva-
tion, behavioral issues in Alzheimer’s disease (AD); hereditary mutation
of the huntingtin (Htt) gene that causes changes in mood and mental
abilities in Huntington’s disease (HD); chronic CNS inflammatory
disease, multiple sclerosis (MS); and inherited non-cell-autonomous
disease called amyotrophic lateral sclerosis (ALS), and also in acute CNS
disorders such as stroke, spinal cord injury, and traumatic brain injury
(TBI).
Loss of blood supply in the brain due to hemorrhage or blood vessel
occlusion is known as stroke. Subsequent neuronal cell death in the
vascular territory of the stroke is caused by the energy depletion due to
occlusion of the residual arteries. The severity of cellular death causes
long-term disability, leading to ischemic stroke being ranked as the
third most frequent case of death following heart disease and cancer at
the 1st and 2nd, respectively (Kriz and Lalancette-Hebert, 2009; Lakhan
et al., 2009). However, the pathophysiology of ischemic stroke is less
understood and demands more attention to reduce infarct progression
over time. In the acute phase, along with decreased cerebral blood flow,
the disrupted cellular ionic homeostasis causes increased intracellular
calcium concentrations and stimulation of glutamate release leading to
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excitotoxicity with inflammation and edema in the ischemic brain
(Anrather et al., 2006; Barone and Feuerstein, 1999; Dirnagl et al.,
1999). Again, ROS produced by the oxidative stress triggered by is-
chemic condition can destroy membranes, mitochondria, and DNA,
which is also a leading cause of cellular death.
Superoxide generation by the immune cells and their consequences
have been suggested to play a key role in the progression of neurode-
generative disorders. The soluble superoxide can combine with other
ROS to induce different neurological disease conditions and form toxic
particles in the diseased environment. In this review, among several
other ROS, we will discuss the superoxide produced by the activation of
NADPH oxidase (NOX) and its inhibitors in both acute and chronic CNS
disorders (Chen et al., 2009). NOX has been reported to produce ROS
more than any other known ROS-producing enzyme including lipox-
ygenase, cyclooxygenases (COX), xanthine oxidase, cytochrome P450,
and substrate-coupled nitric oxide synthetase (Chan, 2004). Thus, many
researchers studying CNS disorders and cell death have paid great at-
tention to the research of the production of ROS by NOX and its me-
chanism in cell death in the recent years. The new discovery of the
diverse NOX homologs have helped researchers in the study of the NOX
enzyme and allowed them to investigate more targeted therapeutic
approaches. However, to date, there are few therapeutic approaches to
treat the NOX-induced ROS-related CNS disorders. This review will
discuss NOX and its inhibitors in relation to CNS diseases and the
therapeutic potential in detail (Table 1).
ROS and NOX in the CNS
ROS play a critical role in normal cellular function in both the de-
veloping and adult brain. Oxygen, a provider of chemical energy, is also
responsible for the formation of ROS through cellular metabolic ac-
tivity. ROS can be produced from the both endogenous and exogenous
sources. Endogenously, can be produced in cellular organelles such as
the mitochondria (mostly in complex I and III), endoplasmic reticulum,
and peroxisome. Enzymes that regulate the non-mitochondrial ROS
production include NADPH oxidase, lipoxygenase, COX, xanthine oxi-
dase, cytochrome P450, and nitric oxide synthetase (Angelova and
Abramov, 2018). In the normal physiological condition, ROS is a by
product of the metabolic system and cellular antioxidant system can
defy ROS’s deteriorative effect and prevent the cellular death. In con-
ditions of oxidative stress, ROS overproduction becomes injurious,
contributing to various acute diseases such as ischemic stroke and
myocardial infarction and chronic diseases related to the cardiovascular
system such as hypertension, atherosclerosis, and neurodegeneration
(e.g., AD, PD).
Among the sources of the cellular ROS production the mitochondrial
system and the NOX system are the major contributor. Mitochondria
use about 1–2% of the daily total cellular oxygen consumption during
Table 1
List of NOX inhibitors and their role on inhibition.
Pharmacological compounds Mode of inhibition Disease Experimented References
Diphenyleneiodonium (DPI) Flavoprotein inhibition Stroke. Spinal Cord Injury (SCI) Nagel et al., 2012, Zehendner et al., 2013
Alzheimer’s Disease (AD) Parkinson’s
Disease (PD)
He et al., 2013; Khayrullina et al., 2015; Qin
et al., 2002
Wang et al., 2015
Blocks NOX Stroke. SCI Heumuller et al., 2008
Apocynin Blocks p47phox to migration. AD, PD Kleinschnitz et al., 2010
Act as antioxidant and anti-inflammatory. ALS Tang et al., 2011; Lull et al., 2011
Ghosh et al., 2012,
Philippens et al., 2013
Trumbull et al., 2012
Honokiol and Plumbagin Increases cytosolic p47phox Stroke. SCI Chen et al., 2016
AD, PD Liu et al., 2015
Decreases membrane p22phox Son et al., 2010
Blocks the interaction of p47phox to NOX2 Stroke. SCI, Traumatic brain injury
(TBI)
Kumar et al., 2016a,b
Nox2ds-tat AD, PD Khayrullina et al., 2015; Cooney et al.,
2014,
He et al., 2011; Askarova et al., 2011; Pal
et al., 2016
Serine protease inhibitors AEBSF Effect directly on the plasma membrane NOX
components
AD Citron et al., 1996
Asthma Gillibert et al., 2005
Interrupts cytosolic p47phox and p67phox binding
Phenylarsine oxide (PAO) Interacts with the vicinal cysteine residues and
inhibits NOX2 building
Paw edema Doussiere et al., 1998, Roussin et al., 1997,
AD Sardar Sinha et al., 2018
Gliotoxin (GT) Blocks p47phox phosphorylation Dagenais and Keller, 2009
Blocks cytoskeleton fusion Tsunawaki et al., 2004
Inhibits of the p67phox, p47phox, and p40phox
translocation
Ebselen Block the p47phox and p67phox translocation to the
plasma membrane
Smith et al., 2012
Herin et al., 2001; Koizumi et al., 2011; Jia
et al., 2018
VAS2870 Inhibit phorbol-12-myristate 13-acetate-dependent
NOX stimulation
Bupivacaine-induced spinal
neurotoxicity
Ten frey et al., 2006
(interfere downstream assembly process but not the
p47phox)
Oshima et al., 2015
HMGCoA reductase inhibitors Inhibit NOX indirectly Stroke Becker et al., 2008
AD, PD Ghosh et al., 2009
Padala et al., 2012
Longenberger and Shah, 2011
S. Barua, et al. IBRO Reports 7 (2019) 59–69
60
cellular respiration to produce superoxide anion radicals in the normal
physiological condition in most tissues (Cadenas and Davies, 2000).
Mitochondrial ROS has two sources which are, the mitochondrial re-
spiratory chain and the mitochondrial outer membrane flavoprotien
named as monoamine oxidase (MAO). The mitochondrial respiratory
chain has 5 complexes in the inner mitochondrial membrane (IMM),
complex I–V (Kim et al., 2015; Quinlan et al., 2013). These membrane
complexes show thermodynamic properties which reduce the O2 to
O2%−, these disproportionating O2%− are the main source of the H2O2.
Usually, Complex I is stimulated by the succinate, a substrate of the
Complex II, produce O2%− in the mitochondrial matrix, and Complex III
in both side of the IMM (Orrenius, 2007). MAO is mostly produces the
highly permeable H2O2, and due to its highly permeable property it can
contribute to the both cytosol and mitochondrial matrix. Due to the
absence of the histone wrapping (as in the nuclear DNA) and closer
proximity the ROS production site, mitochondrial DNA (mtDNA) is a
sensitive target for the oxygen radical attack (Cadenas and Davies,
2000).
NOX, one of the most important enzymes that utilizes molecular
oxygen as a substrate, regulates ROS production in CNS disease when it
is activated. To date, seven NOX paralogues have been reported by
different research groups comprising NOX 1–5, and dual oxidase 1/2
(Duox1/2) (Eun et al., 2017). In the CNS, among the different cell types
neurons, microglia, and intracranial vessels express few of the NOX
paralogues, most prominently NOX2, NOX3, and NOX4 (Chan, 2004).
Among the NOX family, NOX1 and NOX2 are particularly highly ex-
pressed in microglia and NOX3 is least studied and found expressed in
the inner ear but not in blood vessels (Ago et al., 2005; Infanger et al.,
2006). NOX4 is less expressed in neurons and astrocytes but is highly
expressed in the kidneys and vascular smooth muscle cells. NOX5 is
mostly expressed in the spleen and fetal tissues and has been found to
be the least functional isoform of NOX in gene deletion experiments in
rodent (Bedard and Krause, 2007). Duox1/2 were first found in the
thyroid but then later in the immune system, gut, and lung. However,
they are also found in the human neuroblastoma cell line (MO3-13) and
rat brain.
In the mammalian nervous system, NOX paralogues are widely
distributed throughout the cortex, hippocampus, and cerebellum.
Recent studies have revealed that the NOX enzyme complex comprises
four independent cytosolic subunits, p40phox, p47phox, p67phox, and Rac,
and the membrane-bound p91phox and p22phox subunits (Panday et al.,
2015). The activation of the enzyme depends on the proper interaction
of the enzyme complexes where the cytoplasmic p47phox subunit acts as
the major contributor by activating, binding, and docking the other
cytoplasmic subunits to p22phox (Groemping et al., 2003; Groemping
and Rittinger, 2005). The phosphorylation of the p47phox subunit is
very important prior to the activation of the NOX enzyme and diverse
upstream serine kinases, such as p21 and p38-activated kinases (PAK),
PKB/AKT, mitogen-activated kinase (MAPK), cAMP-dependent kinases,
and protein kinase C (PKC) isoforms (α, β, δ, ζ), are known to activate
p47phox (Groemping and Rittinger, 2005). Among these enzymes, the
PKC isoforms are most responsible for the phosphorylation of p47phox.
Upon phosphorylation and binding of p47phox to p91phox, electron
transfer from FAD to heme occurs through redox coupling to generate
superoxide (Tang et al., 2012). However, the p67phox activator subunit
is needed for electron transfer from NADPH to FAD. The hydrogen
peroxide form within phagosomes is also reactive in nature. In the
vascular system, the endothelial, adventitial, and vascular smooth
muscle cells (VSMC) are the main source of ROS, primarily produced by
NOX by catalyzing formation of the superoxide anion (O2%−) in the
reaction: 2O2 + NADPH → 2 O2%−+ NADP + H+ where one electron
reduces the oxygen (Lassegue and Clempus, 2003). The mechanism of
cellular death by superoxide remains poorly understood, but may act
via modulation of the functional properties of critical metabolic pro-
cesses allowing nonselective generation of oxidants such as the hy-
droxyl radical. However, the dramatic attenuation of virulence in SOD
gene deletion studies in bacteria showed that superoxide may directly
kill the bacteria. The inflammatory transcription factor, nuclear factor
kappa B (NFκB) can regulate the expression of NOX and can also induce
gp91phox expression when stimulated by lipopolysaccharide (LPS)
(Anrather et al., 2006). In the non-phagocytic cells AGE-RAGE [ad-
vanced glycation end-product (AGE), receptor of AGE] signaling is re-
lated with the controlled production of ROS via NOX activation (Koulis
et al., 2015; Yamagishi et al., 2012). RAGE signaling also suggested to
be involved in the ROS production via mitochondrial respiratory chain
in AGE treated endothelial cells (Basta et al., 2005).
Studies suggested that mitochondrial ROS and NOX-ROS are related
to each other and one may increase the production of another and vice
versa (Dikalov, 2011). Both mitochondrial and NOX-ROS system are
physically related with the endoplasmic system and in the normal
physiological condition they are very site specific, and exerts their
normal physiological function and on signaling (Santos et al., 2009).
The interaction between the NOX and mitochondrial ROS system con-
stitutes a feed-forward cycle by NOX-derived O2%− in which NOX-ROS
promote the production of Mitochondrial ROS followed by additional
NOX activation and O2%− production (Boulden et al., 2006). Emerging
evidence suggested that the ROS produced by the mitochondria were
considered to be unwanted by product of oxidative metabolism in
contrast to the amount of the ROS produced by the NOX system (Dan
Dunn et al., 2015). Maintenance of the mitochondrial ROS found to be
beneficiary in the cognitive impairment (Glade, 2010) and also pre-
servation of the high locomotor and exploratory activity, and less an-
xiety in animals (Head, 2009; Stefanova et al., 2010). On the other
hand, higher NOX activity, and ROS production were evident in the AD
and PD patients where the neuron and microglial cells might re-
sponsible for the over ROS production and neurological damages (Basta
et al., 2005; Park et al., 2005). Antioxidant treatment targeted the
mitochondrial and NOX-derived ROS production found to be bene-
ficiary in the oxidative damage induced cognitive and locomotive im-
pairment (Head, 2009; Wilkinson and Landreth, 2006). However, fur-
ther studies targeting mitochondrial and NOX-derived ROS production
in CNS disorder are warranted.
Function of NOX in acute and chronic CNS disorders
The presence of NOX isoforms in brain cells and its vasculature
make it a potential therapeutic target in both acute and chronic brain
diseases. NOX enzymes are not only responsible for disease conditions,
but are also involved in essential events in stem cell biology, CNS de-
velopment, and mature neurons, warranting related therapeutic re-
search in CNS disorders. The superoxide produced by NOX in NMDA
excitotoxicity is a popular concept when considering CNS disease pro-
gression. Recently, many studies have reported the involvement of ROS
produced by NOX in acute and chronic disorders.
Ischemic stroke is one of the most critical CNS disorders and is the
3rd leading cause for human death in the world. Stroke is typically di-
vided into two types, hemorrhagic and ischemic. Again the ischemic
stroke can be divided into thrombotic or embolic; ROS production and
ROS-mediated cellular damage is observed in all types of ischemia.
Sudden loss of blood flow in the affected region causes damage to the
mitochondria that cannot be reversed even after reperfusion
(Aronowski et al., 1997; Kuroda and Siesjo, 1997). The rapidly induced
hyperglycemic state in the reperfusion period causes NADPH over-
production through a hexose monophosphate shunt, which causes NOX
activation and increases the production of ROS. The role of the ROS
following reperfusion is depended on the concentration of the ROS
produced. When the ROS production is less it contribute to the normal
cellular physiological fictions (Katsuyama et al., 2012). On the other
hand, the over production of ROS produces oxidative stress which
causes lipid peroxidation, compromised membrane integrity, and or-
ganelle damage, which eventually accelerates cell damage (Nita and
Grzybowski, 2016). Moreover, following ischemia, the cerebral
S. Barua, et al. IBRO Reports 7 (2019) 59–69
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parenchyma is overwhelmed with endogenous microglial activation
and infiltration of peripheral leukocytes. The activated and infiltrating
immune cells can produce superoxide with the help of a list of enzymes,
of which NOX plays the major role. However, mechanism of NOX
phosphorylation in ischemia is not well established yet. However, the
phosphorylation of the p47phox subunit, including several protein ki-
nase C isoforms, p38, p2, and phagocytic NOX2 are thought to be as-
sociated with this phenomenon (Lambeth, 2004). On the other hand, it
is well known that in the inflammatory conditions the ROS is produced
by the infiltrating immune cells via increased expression of pro-in-
flammatory cytokines, such as TNFα (Qin et al., 2004), Interleukin-1β
(Mander et al., 2006), Interleukin-4 (Park et al., 2008a) and Inter-
leukin-13 (Park et al., 2009) or PGE2 (Wang et al., 2004). In the injured
CNS microglia, the expression of NOX2 is increased followed by their
hypersensitivity nature to the proinflammatory cytokines which even-
tually resulted in the higher ROS generation (Surace and Block, 2012).
Pawate et al., suggested that inhibition of the NOX2 in microglial cell
line can suppress the expression of the pro-inflammatory cytokines such
as TNFα, Interleukin-1β, and also attenuate the MAP kinase, and NFκB
phosphorylation which is associated with the reduced ROS production
(Pawate et al., 2004). As in ischemic stroke, oxidative stress and ROS
are the major players with respect to cellular damage in traumatic brain
injury (TBI). In ischemic stroke and TBI models, gp91phox (NOX2) ex-
pression was found to be increased whereas inflammation, oxidative
stress, cellular damage, and secondary damage seem to be attenuated
by NOX2 deletion (Tang et al., 2011; Wang et al., 2013). As TBI is a
more direct injury than any other mechanism, superoxide injury is more
dependent on NOX than any other signaling pathway. In another me-
chanism of oxidative injury in acute brain disease, NMDA receptor
activation has been suggested to be responsible for ROS generation
(Wang et al., 2013). In a previous study, mice with NOX2 deficiency in
circulating blood cells but intact brain NOX2 and vice versa were
subjected to strokes showing that mice with intact brain NOX2 but
lacking circulating NOX2 had better functional outcomes than mice
with intact circulating NOX2, but deficient brain NOX2 (Park et al.,
2007, 2005; Park et al., 2008b).
Chronic inflammation and oxidative stress are related to the pro-
gression of most chronic CNS diseases in which the NOX enzyme family
plays a pivotal role. NOX enzymes modulate the disease progression of
chronic diseases like Alzheimer’s disease (AD) Parkinson’s disease (PD),
and amyotrophic lateral sclerosis (ALS). In the astrocytes and microglia
of the AD brain, NOX expression has been suggested to be increased by
β-amyloid plaques (Bruce-Keller et al., 2010; Clayton et al., 2017; Ma
et al., 2017). However, NOX was not found to have any direct re-
lationship with the development of β-amyloid plaques or neurofi-
brillary tangles, which are important biomarkers of AD. The activation
of NOX enzymes in AD is suggested to be by the phosphorylation of the
p47phox subunit and subsequent translocation to the membrane by β-
amyloid plaques (Shimohama et al., 2000). Recently, it has been sug-
gested that NOX derived ROS (mostly H2O2) in AD are the central
regulator of the cholesterol oxidation product, 24-hydrocholesterol
(Gamba et al., 2011). 24-hydrocholesterol is considered to potentiate
the Aβ mediated pro-apoptotic and pro-necrogenic effects in AD. Mi-
croglial NOX expression and ROS production have been observed in PD
patients and animal models. Yet, neuroinflammation and oxidative
stress were considered to be the root cause of dopaminergic neuron
death and PD progression. Although studies regarding PD pathogenesis
suggested that oxidative stress related to mitochondrial dysfunction
(mitochondrial ROS production) are the leading cause of this disease
and the role od NOX derived oxidative stress is still poorly understood.
Hernan MS. et al., found that in 6-hydroxydopamine induced PD,
higher membrane translocation of the NOX subunit p67phox which
evident the involvement of NOX-derived ROS in PD pathogenesis
(Hernandes and Britto, 2012). Rotenone induced higher activation of
the NOX2 found to increase the accumulation of the alpha-synuclein
aggregation elevating the alpha-synuclein toxicity, a well known
hallmark of the PD (Pal et al., 2016). Excessive activation of the NOX2
by rotenone, increases the production of NOX2-induced ROS that im-
pairs the autophagic flux by reducing the lysosomal activity. Autop-
hagic flux is a crucial process for the clearance of the alpha-synuclein
aggregates. In an another PD study, Zawada et al. reported that an-
giotensin II receptor (Ang II/AT1) levels were increased according to
the disease condition in postmortem examination of pre-PD and PD
patients’ substantia nigra (Zawada et al., 2015). They also suggested
that elevated AT1 levels may activate NOX4, which may be the reason
for substantia nigra neuronal death in PD, suggesting the role of NOX in
PD development and progression. In the spinal cord microglia of animal
ALS (a motor neuron disease) models, the expression of NOX2 mediates
protein oxidation and modulates the neuronal insulin-like growth factor
1 (IGF-1)/Akt survival pathway to ameliorate neuronal damage
(D’Ambrosi et al., 2018; Wu et al., 2006). SOD1, a regulator of NOX,
was also found at increased levels in familial ALS. Marden et al. showed
that mice with G93A SOD1 mutation crossed with NOX1- and NOX2-
null mice can increase the life span of NOX2-null mice over that of
NOX1-null mice (Marden et al., 2007). Thus, the researchers suggested
that NOX is one of the components of ALS pathology. In the prion
(misfolded, aggregated prion protein) infected disease such as Creutz-
feldt-Jakob disease (a transmissible spongiform encephalopathies),
microglial NOX2 related excessive ROS production is the key player of
pathogenesis of this disease. The authors found that in the ex-vivo
cortical slices ablation of the microglial cells reduced the NOX2-derived
ROS, and slower the disease pathogenesis and increse in the neuronal
life span (Sorce et al., 2014). In the early stages of the Huntington's
disease (HD), accessive production of the NOX-derived (specially
NOX2) ROS suggested to be a key player (Valencia et al., 2013). In their
study, the authors suggested that the level of ROS was increased with
the higher NOX activity in HD140Q/140Q (a model of HD mice) primary
neurons and also the rise in the mitochondrial superoxide was de-
pended with the rise in NOX activity. In chronic CNS diseases, NMDA
excitotoxicity can activate NOX, which produces superoxide, and is also
seen in acute CNS disease. The NOX-mediated ROS production via
NMDA receptor overactivation may also be a major mechanism for
chronic CNS disease development and progression. Thus, NOX inhibi-
tion and its subsequent effects have great potential as a target of ther-
apeutic research in acute and chronic CNS diseases.
Pharmacological compounds to inhibit NOX enzymes
Due to the potential role of NOX in the development and progres-
sion of CNS disorders, NOX inhibition is a possible target for the
treatment of various CNS disease. In recent years, a number of chemical
compounds with NOX-inhibitory properties have been studied in the
treatment of acute and chronic CNS disease (Fig. 1). The lower speci-
ficity, selectivity, and relative toxicities of these compounds impede
their use in humans. However, there are a number of specific NOX in-
hibitors found to be safe, and safer alternatives are under development
to be used in humans.
Diphenyleneiodonium (DPI)
DPI, a well-known NOX inhibitor, inhibits superoxide production
through flavoprotein inhibition (Fig. 2B). As a flavoprotein inhibitor,
DPI not only inhibits NOX but also other flavin-dependent enzymes
such as nitric oxide synthase (NOS), xanthine oxidase, and NADH
coenzyme Q reductase. In ischemic stroke, it is also suggested to protect
the brain from stroke by directly suppressing cerebral immunological
responses, maintaining blood-brain barrier (BBB) integrity. The extra-
cellular matrix proteins MMP-2 and MMP-9 are known to disrupt the
BBB. DPI administration in an animal stroke model led to a reduction in
the inflammatory responses and ROS production, along with MMP-2
and MMP-9 expression, while also protecting tight-junction integrity
(Nagel et al., 2007, 2012; Zehendner et al., 2013). In spinal cord injury,
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DPI also reduced lesion size, post-injury inflammation, and the rate of
oligodendrocyte and oligodendrocyte precursor death (Byrnes et al.,
2011; He et al., 2013; Khayrullina et al., 2015)
Enhanced beta-amyloid toxicity caused by microglia in cortical and
mesencephalic neurons (mixed culture) has been reduced by treatment
with DPI (Qin et al., 2002). Beta-amyloid stimulated microglia release
of ATP, which induces ROS production and eventually neuronal death
that is primarily dependent on NOX2. DPI inhibits neuronal death by
inhibiting NOX2 ROS generation and mitochondrial depolarization in
beta-amyloid stimulated astrocytes and neurons (Abramov et al., 2004).
Bianca et al. also reported that DPI is capable of inhibiting H2O2 pro-
duction induced by beta-amyloid in immune cells like the microglia,
monocytes, and neutrophils (Bianca et al., 1999). In Parkinson's dis-
ease, pretreatment with an ultra-low dose of DPI has been found to
reduce progression of neurodegeneration via attenuating microglia-in-
duced chronic neuroinflammation by inhibiting NOX (Wang et al.,
2015). Along with inhibition of the microglia, pretreatment with DPI is
also capable of inhibiting proinflammatory factors and α-synuclein
aggregation. However, due to the inhibitory effect of DPI on many other
metabolic pathway component flavoenzymes in vivo, clinical im-
plementation of DPI has been limited (Kahles et al., 2007).
Apocynin
Apocynin (4-hydroxy-3-methoxy-acetophenone), also known as
acetovanillone, a naturally occurring organic compound of the root of
Canadian hemp (Apocynum cannabinum) and Picrorhiza kurroa, is the
most prominent NOX inhibitor widely used in the treatment of in-
flammatory diseases (Sun et al., 2008). The antioxidant and anti-in-
flammatory methoxy-substituted catechol, apocynin, can block NOX in
both phagocytic and non-phagocytic cells (Zhang et al., 2005), but does
not interfere with the phagocytosis or intracellular killing performed by
neutrophils (Stolk et al., 1994). Apocynin does not block NOX directly,
rather its inhibitory function involves myeloperoxidase (MPO), which
was made evident by MPO deletion experiments. Together with hy-
drogen peroxide, MPO can facilitate the dimerization of the apocynin
that oxidizes thiols in NOX. Thus, apocynin dimer blocks p47phox from
migrating to the membrane, hampering the formation of the enzyme
complex, eventually inhibiting the release of superoxide (Fig. 1A).
However, in MPO deficient cells apocynin can act as a non-specific
oxidative scavenger to ameliorate oxidative stress without NOX in-
hibition (Heumuller et al., 2008). Besides MPO, apocynin dimerization
can also be catalyzed by other peroxidases such as horseradish
Fig. 1. Chemical structure of NOX inhibitors.
Fig. 2. Mode of inhibition of NOX. Apocynin, Nox2ds-tat and Eblesen block p47Phox translocation to the membrane. DPI inhibit the NOX by flavoprotein inhibition.
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peroxidase with successive NOX inhibition. On the other hand, sup-
plementation with glutathione or cysteine as a source of thiols blocks
the inhibitory function of apocynin. Thus, it has been suggested that to
inhibit NOX activity, formation of the apocynin dimer is necessary (Van
den Worm et al., 2001).
Several research groups, including ours, have reported that apoc-
ynin treatment in ischemic stroke can reduce brain hemorrhage, lesion
size, and restore neurological functions. The systemic delivery of
apocynin has also been shown to penetrate the BBB and exert its
function without any impairment (Tang et al., 2008). In our previous
study, we reported that pre-treatment (prior to reperfusion) or post-
treatment (1.5 h after ischemic stroke) with apocynin (2.5 mg/kg)
successfully suppressed superoxide generation in the brain while re-
ducing infarct size and restoring neurological function (Tang XN,Cairns
B,Cairns N and Yenari MA, 2008). On the other hand, a higher dose of
apocynin (3.75 and 5mg/kg), tends to increase the damage after brain
hemorrhage. Other research groups found that apocynin shows some-
what beneficiary effects at a higher dose of 40–50mg/kg (Tang et al.,
2007), and some along us found no effect apocynin using a dose of
about 4mg/kg (Kleinschnitz et al., 2010). Thus, this non-specific dose
range limits the therapeutic usage of apocynin. However, apocynin was
found to be tolerable in single oral doses as high as 1000mg/kg in
normal mice (Pandey et al., 2009). Interestingly, in our NOX2 deletion
study, we found that the beneficial effect of apocynin was absent in
NOX2-deficient mice subjected to stroke, which may suggest that the
function of apocynin is specific to NOX2 (Tang et al., 2011).
The NOX inhibitor, apocynin, has been reported to have neuro-
protective effects in different chronic CNS diseases. In in vitro beta-
amyloid-treated primary neurons, apocynin increased cellular surviva-
bility by reducing expression of proinflammatory cytokines such as
TNF-alpha and IL-1beta (Jekabsone et al., 2006; Li et al., 2004).
Apocynin was also reported to attenuate the cytotoxic effect in familial
AD. However, apocynin alone is not capable of reducing cytotoxicity,
but rather functions in the presence of another NOX inhibitor, oxy-
purinol (Abe et al., 2004). Dumont et al. found that a higher dose of
apocynin (300mg/kg/day) in Tg19959 mice (hAPP695 with the
London and Swedish mutations) did not affect AD plaque formation or
microglial proliferation but reduced the protein carbonyl levels and
increased Rac1 expression. However, a lower dose of apocynin (10mg/
kg/day) in hAPP (751)SL mice (neuron-specific expression of hAPP751
with the London and Swedish mutations) reduced the microglial
number and plaque size (Lull et al., 2011). The above results suggest
that apocynin at a lower dose could be a therapeutic alternative for AD
(Simonyi et al., 2012). In the 1-methyl-4-phenyl-1,2,3,6-tetra-
hydropyridine (MPTP) mouse model of PD, researchers found that
apocynin is capable of blocking microglial and astroglial activation,
along with expression of p91phox in the substantia nigra (Ghosh et al.,
2012). The oral dose of apocynin (100mg/kg/day) improved the hand-
eye coordination and also increased the substantial neuronal surviva-
bility to 8.5% indicating the blocking of the PD progression in MPTP
mouse PD model (Philippens et al., 2013). Like in AD and PD, apocynin
has been found to be effective in the ALS animal models. In the
SOD1G93A transgenic mice model of ALS, apocynin blocked the oxida-
tive stress and increased the life span compared to the wild type mice
(Harraz et al., 2008). Marchetto et al. showed that apocynin can reduce
motor neuron loss caused by mutant SOD1 astrocytes in an in vitro co-
culture ALS model (Marchetto et al., 2008). Prophylactic treatment of
apocynin in SOD1G93A transgenic mouse model of ALS exhibited an
increase in the number of neurons in the spinal cord and life span
prolonged by up to 50% (Harraz et al., 2008). However, another re-
search group suggested that apocynin or diapocynin has a somewhat
limited benefit to SOD1G93A mice (Trumbull et al., 2012). There is not
much evidence of the therapeutic use of apocynin in humans except in a
handful of studies in asthmatics patients who received nebulized
apocynin (Stefanska et al., 2010). Further studies are needed to clarify
the functional specificity of apocynin on NOX isomers and to determine
a functional dose for therapeutic use.
Honokiol and plumbagin
Honokiol ((3′,5-di-(2-propenyl)-1,1′-biphenyl-2,2′-diol) and plum-
bagin (5-hydroxy-2-methyl-1,4-naphthoquinone), the plant quinoid,
are natural bioactive NOX inhibitors derived from Magnolia spp. and
the root of the Plumbago zeylanica L (also known as chitrak), respec-
tively. In both in vivo and in vitro studies honokiol was found to be
neuroprotective against lipid peroxidation and neutrophil infiltration,
which is also accompanied by reduced ROS production (Liou et al.,
2003a,b; Liou et al., 2003a,b). In cancer cell lines, honokiol increased
cytosolic p47phox accumulation and decreased membrane p22phox, re-
sulting in the blocking of NOX1 activation (Prasad et al., 2016). In
stroke, honokiol also inhibits TNF-alpha-induced neutrophil infiltration
of the injury core by inhibiting neutrophil adhesion to the cerebral
endothelial cells (Chen et al., 2016). In spinal cord injury, honokiol
attenuated proinflammatory cytokine expression, microglial activation,
and neutrophil infiltration, eventually improving the functional out-
come (Liu et al., 2015). Plumbagin is the only NOX inhibitor to date
that interacts directly with a specific NOX homolog (Ding et al., 2005).
Plumbagin inhibited the NOX activity in HEK293 and LN229 cells, two
lines that only express NOX4 in a time- and dose-dependent manner.
Superoxide production in NOX4 transfected cells is also blocked by
plumbagin through its direct interaction with NOX4 (Ding et al., 2005).
The mechanism of NOX4 inhibition is not well understood yet. How-
ever, Son et al. suggested that in an in vitro stroke model, plumbagin
may activate the nuclear factor E2-related factor 2 (Nrf2)/antioxidant
response element (ARE) pathway, which provides protection against
oxidative and metabolic insults to neurons (Son et al., 2010). They also
suggested that plumbagin provides protection to neurons in focal is-
chemic injury. ROS production by NOX and NOX homolog expression in
different cancers warrants NOX inhibitors function being referred to as
anti-cancer. Due to its superoxide production blocking property,
plumbagin has been suggested to have significant anti-cancer activity
(Cheng et al., 2001; Hazra et al., 2002; Parimala and Sachdanandam,
1993).
In AD mice, honokiol reduced ROS production, mitochondrial
membrane potential, and increased hippocampal neuronal surviva-
bility, eventually reducing the beta amyloid-induced learning and
memory impairment (Matsui et al., 2009; Talarek et al., 2017; Wang
et al., 2017). The molecular mechanism by which honokiol counteracts
the deleterious effect of beta amyloid in AD is still unknown. However,
researchers have suggested that there are several combined neuropro-
tective effects including reduction of beta-amyloid-induced ROS pro-
duction (Hoi et al., 2010; Talarek et al., 2017), attenuation of Ca2+
influx (Lo et al., 1994; Wang et al., 2013), and inhibition of caspase-3
(Hoi et al., 2010). In the 6−OHDA-lesioned PD mouse model, honokiol
modulated NOS signaling and showed both protective and therapeutic
effects by protecting motor function and dopaminergic cellular viability
(Chen et al., 2018). Treatment with plumbagin in the streptozotocin
(STZ)-induced mouse AD model shows improvement of cognitive
function in an Nrf2/ARE-dependent manner by suppressing astrogliosis
and β-secretase enzyme function (Rodriguez et al., 1998). Plumbagin
inhibits NOX4, the dominant NOX homolog in vascular smooth muscle
cells, explaining its anti-atherosclerotic effect.
Nox2ds-tat
To date, chimeric peptide NOX2ds-tat (NOX2 docking sequence-
tat), formerly known as gp91ds-tat, is the most selective and effective
NOX inhibitor and inhibits NOX in both in vitro and in vivo experiments
(Rey et al., 2001). It is a chimeric 18-amino acid-containing peptide
that was constructed from the sequence of gp91phox; a nine-amino acid
NOX2ds-tat portion of NOX is designed to block the interaction of
p47phox with NOX2 and eventually block the formation of ROS
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(Fig. 1A). NOX2ds-tat is linked with the HIV internalization peptide,
HIVtat, for intercellular delivery (Rey et al., 2001). NOX1 shares the
homology domain with NOX2 and presence of the organizer subunit
p47phox in NOX2, and also binding of the B-loop of NOX2 with the c-
terminal dehydrogenase (DH) domain of NOX4 suggested that NOX2ds-
tat might also block the ROS production by NOX1 and NOX4 (Banfi
et al., 2003; Jackson et al., 2010; Rey et al., 2001). Kumar et al. sug-
gested that NOX2ds-tat reduces oxidative neuronal damage and modi-
fies the M1-/M2-like balance toward neuroprotection in TBI mainly
regulated by NOX2 (Kumar A et al., 2016; Kumar A et al., 2016). In the
rat spinal cord injury model, NOX2 inhibition by NOX2ds-tat blocked
free radical formation and pro-inflammatory cytokine expression and
also helped the functional recovery (Cooney et al., 2014; Khayrullina
et al., 2015). Although NOX2ds-tat does not have any known test per-
formed in stroke, it is known to inhibit oxidative stress that affects the
cerebrovascular system (Park et al., 2007).
In the primary neuron and astrocyte culture, beta amyloid-induced
NMDA receptor excitotoxicity increased Ca2+ influx, ROS production,
and cPLA2 and ERK1/2 and other downstream signaling has been re-
ported to be blocked by the NOX2ds-tat (Askarova et al., 2011; He
et al., 2011). In transgenic Tg2576 AD mice, NOX2ds-tat improved
neurovascular dysfunction and mitigates the behavioral deficits by re-
ducing vascular and neuronal oxidative stress (Park et al., 2008b). Pal
et al. showed that NOX2 da-tat can increase cellular protection by in-
hibiting rotenone-dependent apoptotic cell death and might be used for
treating PD patients (Pal et al., 2016).
Serine protease inhibitors AEBSF
The serine protease enzyme, AEBSF (4-(2-aminoethyl)-benzene-
sulfonyl fluoride), also known as Pefabloc SC, is an irreversible serine
protease inhibitor. AEBSF blocks the formation of the free oxygen ra-
dical by NOX in macrophages and in cell-free systems. In the process of
NOX inhibition, AEBSF does not either interfere with electron transport
or scavenge oxygen radicals but tends to effect NOX components pre-
sent in the plasma membrane directly and by interrupting the binding
of cytosolic components, p47phox and p67phox (Diatchuk et al., 1997).
AEBSF is water soluble and stable, and due to its binding preference can
modify several proteins through highly preferential covalent attach-
ment on tyrosine, and on lysine, histidine, and the amino-terminus to a
lesser extent. There is another irreversible serine protease inhibitor
referred to as tosylphenylalanychloromethane, which shares similar
NOX inhibitory properties as AEBSF (Gillibert et al., 2005). AEBSF is
reported to reduce allergic airway inflammation in allergic asthma,
although there are no studies that tested serine protease inhibitors in
acute CNS models. Citron et al. claimed that AEBSF is specific for
amyloid beta proteins starting with aspartate 1 and capable of directly
inhibiting methionine–aspartate (Met-Asp)-cleaving enzyme b-secretase
(Citron et al., 1996). However, to date, there are no reports of the role
of serine protease inhibitors in chronic CNS disease related to NOX.
Phenylarsine oxide (PAO)
The NOX isoform specificity of PAO has not been determined yet but
it is known as a potent NOX2 inhibitor (Le Cabec and Maridonneau-
Parini, 1995). PAO interacts with the vicinal cysteine residues and only
the NOX2 isoform is suggested to have two neighboring cysteine re-
sidues (positions 368 and 370), which suggests PAO may have speci-
ficity for NOX2 (Doussiere et al., 1998). PAO inhibits NOX by inhibiting
the building of the enzyme complex, suggesting that once NOX is
formed, PAO can not inhibit its function. On the other hand, the in-
hibitory property of the PAO can be reversed by 2,3-dimercaptopro-
panol and not mercaptoethanol (Kutsumi et al., 1995). PAO has been
found to reduce ROS production by rat phagocytes, paw edema induced
by carrageenan, and neutrophil infiltration after lipopolysaccharide
inhalation (Roussin et al., 1997). However, the relationship of NOX2
with these events has not been established yet.
PAO is suggested to be increase sAPPα shedding and decrease the
take-up by exosomes containing toxic amyloid-beta oligomers (Pedrini
et al., 2005; Sardar Sinha et al., 2018). The specific function of soluble
amyloid precursor protein α (sAPPα) is unknown, but the reduction of
toxic amyloid-beta oligomers may decrease neuron-neuron transfer of
AD. There are no studies examining the role of PAO in chronic CNS
diseases, which requires exploration to increase the therapeutic possi-
bilities for those diseases.
Gliotoxin (GT)
The secondary metabolite, gliotoxin, is the sulfur-containing viru-
lence factor of Aspergillus fumigatus. The mode of action of GT is by
blocking p47phox phosphorylation, its fusion with the cytoskeleton, and
membrane translocation of p67phox, p47phox, and p40phox, and also re-
acting with thiol groups, which limits its specificity (Tsunawaki et al.,
2004). Thus, GT also blocks NOX by blocking the assembly of NOX not
through modulation of activated NOX. It also seems to react with thiol
groups, thus limiting its specificity. The mycotoxin GT is suggested to
kill microglia, astrocytes, and neurons via apoptosis, and can also block
ROS production and phagocytosis (Dagenais and Keller, 2009). The
above function of GT and its relationship with NOX has not been tested.
To date, no studies appear to examine the therapeutic value of these
compounds in acute and chronic CNS disease models.
Ebselen
Ebselen (2-phenyl-1,2-benzisoselenazol-3(2 H)-one) is a syntheti-
cally produced organoselenium drug that is also known to inhibit NOX
and is in clinical trials. The glutathione peroxidase-mimicking ebselen
not only inhibits NOX but also a number of other enzymes such as li-
poxygenases, nitric oxide synthases, protein kinase C, and Hz/Kz-
ATPase; therefore, it is known as a non-specific NOX inhibitor
(Cotgreave et al., 1989). It can also react with peroxynitrite. Ebselen
has been suggested to block the translocation of p47phox and p67phox to
the plasma membrane in neutrophils (Smith et al., 2012) (Fig. 1A). It is
considered to have anti-oxidant, anti-inflammatory, and cytoprotective
activity via preventing cellular damage by ROS. It is also reported to be
cytoprotective in NMDA receptor-mediated excitotoxicity (Herin et al.,
2001; Koizumi et al., 2011). For a couple of decades, ebselen has been
used in ischemic stroke clinical trials. It was found to repress lipid
peroxidation and expression of iNOS in the cerebral cortex of a rat
stroke model (Sui et al., 2005; Yamaguchi et al., 1998). It is more ef-
fective in the earlier stages of stroke (Yamaguchi et al., 1998). To date,
some centers in Japan use ebselen for the treatment of stroke and
currently a multicenter phase 3 ebselen trial is ongoing (www.
strokecenter.org). In spinal cord injury, ebselen is suggested to be
neuroprotective via improving mitochondrial function and inhibiting
mitochondrial apoptosis, which eventually reduces secondary injury
(Jia et al., 2018; Kalayci et al., 2005). In a rat TBI model, ebselen im-
proved neurological injury by reducing NO, which also involved the
TLR4-mediated p38 MAPK signaling pathway (Wei et al., 2014).
In AD neurons and mouse brain, ebselen reduced the expression of
APP and β-secretase, which reduced the accumulation of amyloid-beta
and misallocated phosphorylated tau and tau phosphorylation at the
Thr231, Ser396, and Ser404 positions (Xie et al., 2017). Treatment with
ebselen in the STZ-induced mice AD model markedly reduced the
number of apoptotic neurons by reducing oxidative stress (Unsal et al.,
2016). In LRRK2-linked PD, ebselen was found to have neuroprotective
effects via reduction of superoxide and improving peroxidase function
in dopaminergic neurons of drosophila (Angeles et al., 2014).
VAS2870
VAS2870 (3-benzyl-7-(2-benzoxazolyl)thio-1,2,3-triazolo[4,5-d]
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pyrimidine) is one of a few recent NOX inhibitors developed by the
pharmaceutical industry (ten Freyhaus et al., 2006). It was identified as
a specific inhibitor of NOX2 by means of high-throughput screening.
However, Kleinschnitz et al. suggested that VAS2870 is also capable of
inhibiting NOX4 (Kleinschnitz et al., 2010). Later, it appeared to be am
inhibitor of all NOX isoforms, and not a general flavoprotein inhibitor
nor ROS scavenger (Warner et al., 2004). VAS2879 appears to be a pan-
NOX inhibitor. It has been found to inhibit phorbol-12-myristate 13-
acetate-dependent NOX stimulation, which indicates that VAS2870
interacts downstream of the assembly process but not with p47phox (ten
Freyhaus et al., 2006; Wingler et al., 2019). In preclinical stroke ex-
periments, VAS2870 has been shown to be neuroprotective against
inhibition of NOX4 (Kleinschnitz et al., 2010). A recent study suggested
that VAS2870 alkylates cysteine thiol residues, as it was shown to have
potential off-target effects. In bupivacaine-induced spinal neurotoxicity,
VAS2870 was found to reverse all changes and attenuate all neuronal
toxicity by inhibiting p47phox membrane translocation (Li et al., 2017).
In uric acid-, indoxyl sulfate-, and methylguanidine-stimulated bul-
bospinal RVLM neurons, the oxidative stress-induced neurotoxicity has
been suggested to be suppressed by the VAS2870 by inhibiting NOX2
and NOX4 (Oshima et al., 2015).
HMGCoA reductase inhibitors
HMGCoA (3-hydroxy-3-methyl-glutaryl-coenzyme A) reductase is a
rate-limiting enzyme that is involved in the synthesis of cholesterol in
the liver. There are several HMGCoA reductase inhibitors, such as
pravastatin, fluvastatin, atorvastatin, simvastatin, and rosuvastatin,
that are found as the mainstay of therapy for high LDL cholesterol,
coronary disease, and stroke. Along with the HMGCoA reductase in-
hibitor (statins), angiotensin converting enzyme (ACE) inhibitors and
angiotensin receptor-1 blockers (ARBs) can also indirectly inhibit NOX
activity (Wagner et al., 2000). All of the above clinically tested drugs
have been shown to protect the brain from experimental stroke through
different mechanisms. However, statins have been shown to exert their
neuroprotective function in experimental stroke via their ability to
upregulate endothelial nitric oxide synthase (Li et al., 2014). All of
these compounds, besides their lipid lowering capabilities, have been
shown to act as anti-inflammatory agents, affect endothelial function,
and modulate the coagulation cascade (Bedi and Flaker, 2002). How-
ever, whether this is directly due to NOX inhibition seems less likely,
with these compounds acting as related immune targets.
Several studies have suggested the use of HMGCoA reductase in-
hibitors in the treatment of AD. The principle behind statins reducing
the prevalence of AD is by lowering the build-up of brain cholesterol,
eventually reducing amyloid beta aggregation (Longenberger and Shah,
2011). However, Sparks et al. and a few other studies have suggested
that the use of statins would be less advised as statins may reduce the
production of essential cholesterols in the AD patients, which may ex-
acerbate AD degeneration and also adversely affect cognition in AD
patients (Padala et al., 2012). The statins may modulate PD in several
ways such as by inhibiting proinflammatory stimulation (Ghosh et al.,
2009), upregulating eNOS (Feron et al., 2001), reducing NOX-mediated
production of ROS through the inhibition of geranylgeranylation of Rac
(Gao et al., 2003; Wu et al., 2003), and attenuating α-synuclein ag-
gregation (Bar-On et al., 2008; Roy and Pahan, 2011). On the other
hand, studies have suggested that the long-term use of statins does not
alter the relative risk of developing PD (Becker et al., 2008).
Conclusion
NOX appears to be an important player in CNS disorders, particu-
larly as it is related to the generation of superoxide, which is the major
modulator of acute and chronic CNS diseases. Several preclinical stu-
dies have reported that the inhibition of NOX improved neurological
outcomes and reduced severity of brain injury in both acute and chronic
cases. However, most of the available inhibitors may be non-specific
with a relatively narrow therapeutic window that warrants greater in-
vestigation of NOX inhibitors and studies to develop safe and selective
drugs for the treatment of clinical CNS diseases. It is also very important
to study the complications and adverse effects of the available NOX
inhibitors and the difference in benefits among them as well.
Furthermore, with the knowledge that the facts of the role of various
NOX isoforms is rapidly increasing, such facts could also drive the de-
velopment of appropriate therapies as well.
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